药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
4-Methoxyamphetamine
Aripiprazole lauroxil
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Aripiprazole lauroxil.
4-Methoxyamphetamine
Pipemidic acid
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Pipemidic acid.
4-Methoxyamphetamine
Rufloxacin
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Rufloxacin.
4-Methoxyamphetamine
Lidoflazine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Lidoflazine.
4-Methoxyamphetamine
Piromidic acid
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Piromidic acid.
4-Methoxyamphetamine
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Acetyldigoxin.
4-Methoxyamphetamine
Lorajmine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Lorajmine.
4-Methoxyamphetamine
Oxolinic acid
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Oxolinic acid.
4-Methoxyamphetamine
Prajmaline
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Prajmaline.
4-Methoxyamphetamine
Bencyclane
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Bencyclane.
4-Methoxyamphetamine
Cibenzoline
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Cibenzoline.
4-Methoxyamphetamine
Gallopamil
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Gallopamil.
4-Methoxyamphetamine
Cicletanine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Cicletanine.
4-Methoxyamphetamine
Pilsicainide
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Pilsicainide.
4-Methoxyamphetamine
Givinostat
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Givinostat.
4-Methoxyamphetamine
Triclabendazole
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Triclabendazole.
4-Methoxyamphetamine
Temefos
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Temefos.
4-Methoxyamphetamine
Tetrahydropalmatine
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Tetrahydropalmatine.
4-Methoxyamphetamine
Prulifloxacin
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Prulifloxacin.
4-Methoxyamphetamine
CUDC-907
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with CUDC-907.